Takeaways
- Real-time continuous glucose monitoring reduced the proportion of large-for-gestational-age births compared with self-monitoring of blood glucose in a multicenter randomized trial.
- Small-for-gestational-age births occurred more often than expected in both groups, suggesting the need to evaluate glycemic targets to avoid insufficient fetal growth.
- Serious adverse events were similar between groups, indicating that real-time continuous glucose monitoring was not associated with additional safety concerns during pregnancy.
An international, multicenter randomized controlled trial has found that real-time continuous glucose monitoring (rt-CGM) lowered the proportion of large-for-gestational-age (LGA) births among women with gestational diabetes compared with self-monitoring of blood glucose (SMBG). The findings, published in The Lancet Diabetes & Endocrinology, provide new evidence to inform glucose monitoring approaches during pregnancy.1,2
According to the Medical University of Vienna, the trial represents “the first multicenter randomized controlled trial to demonstrate the advantages of the digital method over conventional self-monitoring of blood glucose using finger pricks and opens up new perspectives for the targeted care of women with gestational diabetes.”
Study design and population
The open-label, parallel-group study recruited women aged 18 to 55 years with singleton gestations and gestational diabetes diagnosed according to International Association of the Diabetes and Pregnancy Study Groups criteria. Participants were enrolled at 4 university hospitals in Austria, Germany, and Switzerland. A total of 375 women were randomly assigned to rt-CGM (n=190) or SMBG (n=185), with randomization structured to balance gestational age at entry, prior gestational diabetes, and preconception body mass index.
Participants assigned to SMBG used blinded CGM for 10 days after randomization and again at 36 to 38 weeks’ gestation, while the rt-CGM group used open rt-CGM until delivery. All participants received standard gestational diabetes management according to clinical guidelines.
The mean gestational age at gestational diabetes diagnosis was 25.2 weeks (SD, 2.3), and the mean gestational age at randomization was 28.6 weeks (SD, 1.9).
Primary outcome: Large-for-gestational-age births
In the intention-to-treat population, LGA births occurred in 4% (6 of 170) of the rt-CGM group compared with 10% (18 of 175) of the SMBG group (OR, 0.32; 95% CI, 0.10–0.87; P = .014). The Medical University of Vienna noted that “only 4% of women in the rt-CGM group gave birth to an above-average weight child...compared with ten percent in the control group.” Average birthweight percentiles were also lower in the rt-CGM group.